West Chester Capital Advisors Inc Exits Position in Gilead Sciences (GILD)

Gilead Sciences (GILD) : West Chester Capital Advisors Inc has sold out all of its stake in Gilead Sciences during the most recent quarter, according to the disclosure filed by the company on Aug 8, 2016 with the SEC. The investment management company has sold out 11,528 shares of Gilead Sciences which is valued at $917,283.

Other Hedge Funds, Including , Fayerweather Charles boosted its stake in GILD in the latest quarter, The investment management firm added 1,784 additional shares and now holds a total of 6,998 shares of Gilead Sciences which is valued at $556,831. Gilead Sciences makes up approx 0.76% of Fayerweather Charles’s portfolio.Rfg Advisory Group reduced its stake in GILD by selling 10 shares or 0.17% in the most recent quarter. The Hedge Fund company now holds 6,004 shares of GILD which is valued at $480,860. Gilead Sciences makes up approx 0.41% of Rfg Advisory Group’s portfolio.Penobscot Investment Management Company boosted its stake in GILD in the latest quarter, The investment management firm added 470 additional shares and now holds a total of 6,491 shares of Gilead Sciences which is valued at $515,840. Gilead Sciences makes up approx 0.18% of Penobscot Investment Management Company’s portfolio.Westend Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 35,826 additional shares and now holds a total of 1,118,400 shares of Gilead Sciences which is valued at $88,879,248. Gilead Sciences makes up approx 4.55% of Westend Advisors’s portfolio.Gofen Glossberg Il reduced its stake in GILD by selling 6,100 shares or 1.96% in the most recent quarter. The Hedge Fund company now holds 305,498 shares of GILD which is valued at $26,196,454. Gilead Sciences makes up approx 1.08% of Gofen Glossberg Il’s portfolio.

Gilead Sciences closed down -0.01 points or -0.01% at $79.65 with 74,64,775 shares getting traded on Monday. Post opening the session at $79.88, the shares hit an intraday low of $79.43 and an intraday high of $80.09 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *